Diabetica

Diabetica is a clinical-stage biotechnology company focused on the prevention and treatment of diabetic complications through the management of advanced glycation end-products (AGEs). The company utilizes a proprietary platform to measure methylglyoxal and other glycation precursors to identify patients at high risk for kidney and eye disease. Diabetica's approach combines diagnostic testing with therapeutic interventions aimed at reducing the toxic effects of glycation in diabetic patients. The company's lead diagnostic product, Glyco-S, is designed to predict the risk of diabetic nephropathy years before clinical symptoms appear, allowing for early intervention and personalized treatment strategies.